NCT00107237View on ClinicalTrials.gov

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

AEE788

AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.

DRUG

everolimus

Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.

Trial Locations (3)

27710

Duke Univaersity Medical Center, Durham

77030

MD Anderson Cancer Center/University of Texas, Houston

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY